Dasatinib in Resectable Malignant Pleural Mesothelioma
Status:
Unknown status
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn how dasatinib affects biomarker levels
in patients with malignant pleural mesothelioma that may be able to be removed by surgery.
The safety and effectiveness of this drug will also be studied.
This research study is financially supported by the United States Department of Defense.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Bristol-Myers Squibb United States Department of Defense